Using ERAP to disrupt the interaction between PHB2 and BIG3 can stop breast cancer cells that are positive for ERα from growing and make these cells more responsive to tamoxifen (Yoshimaru et al., 2013). Here, PHB2 is linked to breast carcinoma.